The National Institute of Public Health (FHI) has decided that the pause in the use of AstraZeneca vaccines will be extended by three weeks due to the possible serious side effects.
“We have decided to continue the pause and make a new decision by April 15,” FHI director Camilla Stoltenberg told Norwegian Broadcasting (NRK).
“We believe it is necessary to carry out more investigations into the relevant incidents so that we can give the best possible advice on vaccination to the population in Norway,” infection control director Geir Bukholm at the FHI noted.
The vaccine has not been used in Norway since March 11 after reports of severe blood clots and deaths were linked to the vaccine.
Investigations in progress
The FHI and the health authorities in several countries are now investigating the connection. Several other countries have resumed vaccination while the investigations are ongoing.
The European Medicines Agency (EMA) decided on March 18 to maintain the approval of the AstraZeneca vaccine.
The EMA considers that the benefits are high and that the reported side effects are rare, but points out that serious cases of rare side effects cannot be ruled out.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at email@example.com